1/43
Looks like no tags are added yet.
Parkinson’s treatments
DA Replacement
LEVODOPA
Peripheral decarboxylase
inhibitor: CARBIDOPA
COMT inhibitor
entacapone
MAO B inhibitor
selegiline (Deprenyl)
DA receptor agonist
ROPINIROLE (Requip®)
Bromocriptine
Parkinson’s motor symptoms
progressive disease
Tremor of rest
Bradykinesia, Rigidity
Postural defect: tendency to stoop
Expressionless face
Mortality: due to complications of severe
rigidity
Parkinson’s nonmotor symptoms
Autonomic dysfunction (constipation)
Sleep Disorder
Dementia
Depression
Lack of Impulse Control, Psychosis
Pathophysiology of Parkinson’s
Progressive degeneration of neurons in the
Substantia Nigra (Pars Compacta): loss of DA
transmission
clear model of disease using MPTP toxicity
DA/ACh balance
2 classes of dopamine receptors
D1 receptors (excitatory)
D2 receptors (inhibitory)
D1 and D2 Regulation of Basal
Ganglia output to the Thalamus
Direct pathway dominated by D1 receptors, Indirect Pathway dominated
by D2 receptors—both affect thalamic stimulation of the cortex
goal of therapy
Re-establish balance of
striatal signaling
Increase DA signaling
Decrease mACh signaling
Levodopa (L-DOPA)
DA precursor
crosses blood brain barrier
actively taken up into neurons (aa
transporter)
converted to DA by DA decarboxylase
Bypasses the rate-limiting step (tyrosine
hydroxylase)
tyrosine hydroxylase
converts tyrosine —> DOPA
amino acid decarboxylase
converts DOPA —> dopamine
MAO
converts dopamine —> DOPAL
also converts norepinephrine —> DOPGAL
dopamine beta-hydroxylase
converts dopamine —> norepinephrine
adverse effects of LEVODOPA
dyskinesia
hallucinations/confusion
Drug interaction with classical
antipsychotics that inhibit DA receptors
Can cautiously treat psychosis with
clozapine (no D2 effects)
peripheral effects: nausea (DA
receptors in gut), hypotension
(unknown cause), arrhythmia
LEVODOPA dajunct therapy
treat w/ carbidopa (peripheral inhibitor of L-amino acid decarboxylase
prevents conversion to DA in periphery
does not cross blood-brain barrier
reduces peripheral side effects (i.e.
nausea) and allows more drug to reach
brain
Carbidopa effects on DA reaching
the brain
Increases the
fraction of drug that
reaches the brain
Greatly reduces the
dose required
LEVODOPA adjunct therapy
use entacapone, which inhibits COMT (catechol-o-methyl transferase) in periphery
Prevents degradation of LEVODOPA
Adverse effects: dyskinesia, nausea and diarrhea
combination therapy
LEVODOPA
Carbidopa
(DDC inhibitor)
Entacapone
efficacy of LEVODOPA
Extremely effective early in
treatment
over time development of motor
fluctuation
possibly receptor adaptation
effect reduced by increasing number of
dosages
selegiline
MAO B inhibitor
prevents metabolism of DA, NE, and 5-HT
reduces does of LEVODOPA needed
adverse effects of selegiline
Has some amphetamine-like side effects
(partly metabolized to amphetamine)
metabolized in the liver by cytp450
enzymes
bromocriptine
other form of Parkinson’s treatment
ergot alkaloid
DA receptor agonist
treatment for Parkinson’s
activity at D1, D3, and 5-HT
Similar side effects to levodopa with more risk of
psychotic effects
Risk of cardiac valve fibrosis in long-term use
ropinirole
Less selective than Bromocriptine:
has D2, D3, D4 receptor agonist
activity
Also useful treatment for Restless
Leg Syndrome
adverse effects of ropinirole
Metabolized by Cytp450 thus could
cause drug interactions
Mostly has replaced Bromocriptine
therapeutically due to reduced side
effects
COMT
upregulated, used as add-on after L-DOPA therapy
classical D2 antagonists
HALOPERIDOL
• Treatment for Neuroleptic Malignant Syndrome: BROMOCRIPTINE
atypical antipsychotics
• RISPERIDONE
• CLOZAPINE
• QUETIAPINE
• ARIPIPRAZOLE (Abilify™): Atypical D2/5HT partial agonist
dopamine hypothesis
all classical antipsychotics block D2 receptors
Parkinson’s patients treated w/ L-DOPA may have psychotic side effects
excess DA signaling
causes “positive symptoms” of schizophrenia
classical antiphychotics
D2 recpetor antagonists
mech: blocks excessive DA function in limbic system
replaced by Haloperidol (side effects)
haloperidol
sedation: early onset, tolerance
hypotension
extrayramidal effects:
tremor, akinesia, akathisia, tardive dyskinesia (late onset, can be irreversible)
neuroleptic malignant syndrome (autonomic deregulation)
neuroleptic malignant syndrome
runs in families
hyperpyrexia
autonomic instability
confusion
higher creatine kinase levels
neuroleptic malignant syndrome treatment
often in ICU
aggressive IV hydration and diuresis w/ bromocriptine
motor vs metabolic side effects
it’s a trade-off
Second-generation antipsychotics have improved effectiveness for
emotional withdrawal and fewer motor effects
• second-generation agents can produce adverse metabolic
changes
• Weight gain
• Hyperlipidemia
• Diabetes
2nd gen atypical antipsychotics (clozapine)
blocks D4=5-HT2=alpha=mACh=H
low potency
used for patients who develop dyscrinesia or Parkinson’s
most effective
2nd gen atypical antipsychotics (risperidone)
blocks D2=5-HT2 (better for negative symptoms)
2nd gen atypical antipsychotics (quetiapine/seroquel)
antagonist to D1, D2, 5-HT1A, and 5-HT2
similar to risperidone
side effects: very sedating
choice for people w/ sleep disorders
2nd gen atypical antipsychotics (aripiprazole)
newest antipsychotics
D2 and 5-HT1 partial agonist/antagonist (good b/c they don’t make symptoms severe)
#1 drug in sales, heavily marketed for depression
adverse effects of aripiprazole
less weight gain
metabolized by cytP450, so it can have drug interactions
summary of antipsychotics
all are effective in mania
clozapine most effective overall
aripiprazole also effective in depression
other uses for antipsychotics
Tourette’s
Huntington’s (progressive DA degeneration)
Haloperidol is drug of choice